US 12,227,770 B2
Alphavirus replicon particle
Wataru Akahata, Kensington, MD (US); and Ryuji Ueno, Easton, MD (US)
Assigned to VLP Therapeutics, Inc., Wilmington, DE (US)
Filed by VLP Therapeutics, Inc., Wilmington, DE (US)
Filed on Sep. 22, 2021, as Appl. No. 17/481,495.
Application 17/481,495 is a continuation of application No. 16/225,181, filed on Dec. 19, 2018, abandoned.
Claims priority of provisional application 62/608,213, filed on Dec. 20, 2017.
Prior Publication US 2022/0002682 A1, Jan. 6, 2022
Int. Cl. C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)
CPC C12N 7/00 (2013.01) [A61K 39/001162 (2018.08); A61K 39/12 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C07K 16/2818 (2013.01); C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2770/36122 (2013.01); C12N 2770/36123 (2013.01); C12N 2770/36134 (2013.01); C12N 2770/36143 (2013.01); C12N 2770/36152 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method for introducing a gene of interest into a cell in a subject in need thereof, which comprises administering to the subject an alphavirus replicon particle (ARP), which comprises
(i) alphavirus structural proteins, wherein said alphavirus structural proteins comprise capsid protein, and E1 and E2 envelope proteins, and
(ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus nonstructural proteins nsp1, nsp2, nsp3 and nsp4 and at least one gene of interest,
wherein said alphavirus capsid protein contains a mutation in the Nuclear Localization Signal (NLS), and wherein said mutation is the substitution of lysine with asparagine at the position corresponding to position 64 of VEEV virus capsid protein.